Prelude Therapeutics Incorporated
NASDAQ:PRLD
0.7069 (USD) • At close March 13, 2025
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Omzet
| 7 | 0 | 0 | 0 | 0 | 0 | 0 |
| Kosten van de omzet
| 0 | 1.169 | 3.042 | 2.243 | 0.542 | 0.382 | 0.149 |
| Brutowinst
| 7 | -1.169 | -3.042 | -2.243 | -0.542 | -0.382 | -0.149 |
| Brutowinstmarge
| 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Onderzoek- en ontwikkelingskosten
| 117.995 | 103.393 | 92.889 | 86.778 | 48.177 | 24.279 | 12.621 |
| Algemene en administratieve kosten
| 28.719 | 28.884 | 30.651 | 26.957 | 10.586 | 3.83 | 2.354 |
| Verkoop- en marketingkosten
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Verkoop-, algemene en administratieve kosten
| 28.719 | 28.884 | 30.651 | 26.957 | 10.586 | 3.83 | 2.354 |
| Overige kosten
| 0 | -0 | 8.102 | 2.041 | 1.834 | 0.539 | 0.295 |
| Bedrijfskosten
| 146.714 | 132.277 | 123.54 | 113.735 | 58.763 | 28.109 | 14.975 |
| Bedrijfsresultaat
| -139.714 | -132.277 | -123.54 | -113.735 | -58.763 | -28.109 | -14.975 |
| Bedrijfsresultaat ratio
| -19.959 | 0 | 0 | 0 | 0 | 0 | 0 |
| Totaal overige inkomsten en kosten netto
| 12.541 | 10.445 | 8.102 | 2.041 | 1.834 | 0.539 | 0.295 |
| Inkomen voor belasting
| -127.173 | -121.832 | -115.438 | -111.694 | -56.929 | -27.57 | -14.68 |
| Inkomen voor belasting ratio
| -18.168 | 0 | 0 | 0 | 0 | 0 | 0 |
| Belastingkosten
| 0 | 0 | -8.102 | -0.915 | 0.336 | 0.21 | 0.295 |
| Nettowinst
| -127.173 | -121.832 | -107.336 | -110.779 | -56.929 | -27.57 | -14.68 |
| Nettowinstmarge
| -18.168 | 0 | 0 | 0 | 0 | 0 | 0 |
| WPA (Winst Per Aandeel)
| -1.68 | -2.02 | -2.27 | -2.33 | -1.3 | -0.85 | -0.46 |
| Verwaterde WPA
| -1.68 | -2.02 | -2.27 | -2.33 | -1.3 | -0.85 | -0.46 |
| EBITDA
| -139.714 | -131.108 | -122.216 | -112.82 | -58.221 | -27.727 | -14.826 |
| EBITDA ratio
| -19.959 | 0 | 0 | 0 | 0 | 0 | 0 |